Related Experiment Video
Updated: Aug 19, 2026
Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
[Pseudomyxoma peritonei: new concept and new therapeutic approach]
R Loungnarath1, S Causeret, C Brigand
1Département de chirurgie colorectale, centre hospitalier de l'université de montréal, hôpital Saint-Luc, Montréal, Québec, Canada.
Abstract:
Pseudomyxoma peritonei is a rare disease, usually diagnosed after the discover of "jelly belly" by laparotomy. With the progress of immunohistochemistry, most authors now acknowledge the appendix to be the principal origin of this disease. Pseudomyxoma peritonei need to considered as border line malignant disease because of its inevitable persistence and progression without adapted therapeutic approach: cytoreductive surgery combined with perioperative intraperitoneal chemotherapy (intraperitoneal chemohyperthermia and/or immediate postoperative intraperitoneal chemotherapy) into specialized centres. The principal prognostic factors are the prior surgical history, the completeness of cytoreduction and especially the histopathologic grade.
Insights
Pseudomyxoma peritonei, a rare condition often called "jelly belly," typically originates from the appendix. Effective treatment involves cytoreductive surgery and specialized intraperitoneal chemotherapy.
Area of Science:
- Oncology
- Gastroenterology
- Surgical Pathology
Context:
- Pseudomyxoma peritonei (PMP) is a rare clinical entity.
- Diagnosis is often incidental during laparotomy, revealing characteristic "jelly belly" ascites.
- The appendix is now widely accepted as the primary origin of PMP.
Purpose:
- To discuss the classification and management of Pseudomyxoma peritonei.
- To highlight the role of cytoreductive surgery and perioperative intraperitoneal chemotherapy.
- To identify key prognostic factors in PMP.
Summary:
- PMP is considered a borderline malignant disease due to its progressive nature without appropriate treatment.
- The standard therapeutic approach involves cytoreductive surgery combined with perioperative intraperitoneal chemotherapy (hyperthermia and/or postoperative instillation).
- Treatment should be performed in specialized centers.
Impact:
- Understanding the appendiceal origin and borderline malignant nature of PMP is crucial for management.
- Cytoreductive surgery and specialized chemotherapy offer a therapeutic strategy for this rare condition.
- Prognostic factors including surgical history, cytoreduction completeness, and histopathologic grade guide patient outcomes.
More Related Videos
07:20Intraoperative Detection of Subtle Endometriosis: A Novel Paradigm for Detection and Treatment of Pelvic Pain Associated with the Loss of Peritoneal Integrity
Published on: December 21, 2012
11:34Modeling Ovarian Cancer Multicellular Spheroid Behavior in a Dynamic 3D Peritoneal Microdevice
Published on: February 18, 2017